News
  Date Title View
Apr 29, 2015
BURLINGTON, Mass., April 29, 2015 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that the U.S. Department of Defense ("DoD") awarded the company a grant1 worth approximately $2 million to conduct a Phase 2 clinical trial investigating FX006 as treatment for osteoarthritis ("OA") pain in active military and medically re...
Apr 8, 2015
BURLINGTON, Mass., April 8, 2015 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Michael Clayman, M.D., President and Chief Executive Officer, will present at the 14th Annual Needham Healthcare Conference on Wednesday, April 15, 2015 at 12:50 a.m. Eastern Time at The Westin NY Grand Central Hotel in New York, NY. ...
Mar 23, 2015
Strong cash position bolstered through IPO and follow-on financing, raising a combined total of over $173 million Lead drug candidate FX006 advanced into late-stage pivotal trials for patients with osteoarthritis (OA) of the kneeBURLINGTON, Mass., March 23, 2015 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced financial ...
Mar 16, 2015
BURLINGTON, Mass., March 16, 2015 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that it will host a conference call and webcast to report its year-end 2014 financial results on Monday, March 23, 2015, at 4:30 p.m. ET. The dial-in number for the conference call is (855) 770-0022 for domestic participants and (908) ...
Mar 6, 2015
- Scott Canute, Former President of Global Manufacturing at Eli Lilly and Company and Subsequently at Genzyme Corporation, Appointed New Board Member -- Flexion CEO Michael Clayman Offers Thanks to Departing Board Member Andrew Schwab - BURLINGTON, Mass., March 6, 2015 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today...
Feb 24, 2015
BURLINGTON, Mass., Feb. 24, 2015 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that it has completed enrollment in its pivotal Phase 2b confirmatory clinical trial designed to further evaluate the safety, tolerability and efficacy of FX006 as a treatment for relieving pain associated with OA of the knee. FX006 is Flex...
Feb 17, 2015
BURLINGTON, Mass., Feb. 17, 2015 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Michael Clayman, M.D., President and Chief Executive Officer, will present at the RBC Capital Markets Healthcare Conference on Tuesday, February 24, 2015 at 9:00 a.m. Eastern Time at The New York Palace Hotel in New York, NY. To ac...
Feb 2, 2015
BURLINGTON, Mass., Feb. 2, 2015 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced dosing of the first patient in the Phase 3 clinical trial of its lead drug candidate FX006 as a treatment for pain associated with osteoarthritis (OA) of the knee. FX006 is Flexion's novel, non-opioid, sustained-release, intra-articular (IA ...
Dec 17, 2014
BURLINGTON, Mass., Dec. 17, 2014 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the closing of its previously announced underwritten public offering. A total of 5,796,000 shares of the Company's common stock were sold in the offering at a price to the public of $17.00 per share. The shares include 756,000 shares of com...
Dec 12, 2014
BURLINGTON, Mass., Dec. 12, 2014 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the pricing of its underwritten public offering of 5,040,000 shares of common stock at a price to the public of $17.00 per share. Flexion has also granted the underwriters a 30-day option to purchase up to an additional 756,000 shares of co...
FirstPrevious ...
10
... NextLast
= add release to Briefcase